Pediatr Infect Dis J 2021 Jul 27. Epub 2021 Jul 27.
From the AMS-PHPT Research Collaboration, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt PENTA Foundation, Padova, Italy Department, NEUROFARBA, University of Florence, Florence, Italy Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland; and Pediatric Department, Ain Shams University, and Faculty of Medicine, Ain Shams University Research Institute Clinical Research Center (MASRI-CRC), Cairo, Egypt.
Background: Sofosbuvir (SOF)/daclatasvir (DCV) is the direct-acting antiviral regimen of choice in many low- and middle-income countries for curative treatment of chronic hepatitis C virus (HCV) infection in adults, but data on the use of DCV in children are lacking. We performed a population pharmacokinetic (PK) analysis to predict DCV exposure in children treated with available adult formulations.
Methods: DCV concentration data from HCV-infected adolescents receiving SOF/DCV [400/60 mg, once daily (OD)] who participated in a PK study in Egypt were used for model development. Read More